Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287644 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Bluefin Biomedicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 4
- Study locations
NCT07287644 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Bluefin Biomedicine. The registered enrollment target is 210 participants, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (29% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT07287644, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Bluefin Biomedicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Conditions Studied
Interventions
- BIOLOGICAL BFB759
- OTHER Placebo for BFB759
Study Locations (4)
Florida
- Skin Care Research - Boca Raton
- Ziaderm Research LLC - North Miami Beach
- Clinical Trials Management, LLC - Tampa
Louisiana
- Clinical Trials Management, LLC - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07287644
The ClinicalTrials.gov registry entry for NCT07287644 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (29% higher). The listed sponsor is Bluefin Biomedicine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which BFB759 is the first listed.
NCT07287644 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT07287644 about?
NCT07287644 is a clinical study titled "A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa". This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
What is the current status of trial NCT07287644?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2025-11-03. Estimated completion is 2027-08-01.
What conditions does trial NCT07287644 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT07287644?
The interventions under investigation include: BFB759 (BIOLOGICAL), Placebo for BFB759 (OTHER).
Who is sponsoring clinical trial NCT07287644?
This trial is sponsored by Bluefin Biomedicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287644 being conducted?
This trial has 4 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.